A Phase I/II Study of Chemo Radiation Plus the Anti-Programmed Death-1 (Anti-PD-1) Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Laryngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 Jan 2020.
- 14 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2020.
- 05 May 2016 New trial record